8-K: Current report filing
Published on May 29, 2019
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 28, 2019
REXAHN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
charter)
| Delaware |
|
001-34079
|
|
11-3516358
|
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
15245 Shady Grove Road, Suite
455 Rockville, MD
|
20850
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (240) 268-5300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| ☐ |
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| ☐ |
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, $0.0001 par value
|
RNN
|
NYSE American
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
|
Emerging growth company ☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 3.01 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
On May 28, 2019, the Board of Directors (the “Board”) of Rexahn Pharmaceuticals, Inc. (the “Company”)
approved the voluntary transfer of the Company’s listing of its common stock, par value $0.0001 per share (“Common Stock”), from NYSE American to the Nasdaq Capital Market (“Nasdaq”). The Common Stock has been approved for listing by Nasdaq and
the Company provided written notice to NYSE American of its intention to cease trading on NYSE American at market close on June 7, 2019. The Company expects to commence trading on Nasdaq on June 10, 2019 under the ticker symbol “REXN”.
| Item 7.01 |
Regulation FD Disclosure.
|
On May 28, 2019, the Company issued a press release announcing the transfer of the listing of its Common
Stock to Nasdaq. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
Press release dated May 28, 2019.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
Rexahn Pharmaceuticals, Inc.
|
||
|
|
||
|
By:
|
/s/ Douglas J. Swirsky
|
|
|
Douglas J. Swirsky
|
||
|
President and Chief Executive Officer
|
||
| Dated: May 29, 2019 | ||